Evidence map›Paper›PMID 34394127›Full record

ArticleFrontiers in immunology2021

Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.

Antonella Scaglione, Silvana Opp, Alicia Hurtado, Ziyan Lin, Christine Pampeno, Maria G Noval, Sara A Thannickal, Kenneth A Stapleford, Daniel Meruelo

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Arboviruses in Cancer therapy: pros and cons.Journal of neurovirology · 2026
    Review
  3. Review
  4. Review
  5. Rational design of self-amplifying virus-like vesicles with Ebola virus glycoprotein as vaccines.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  6. Review
  7. Article
  8. Review
  9. Reader comments.Proceedings (Baylor University. Medical Center) · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Antonella ScaglioneDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, United States.
Silvana OppDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, United States.
Alicia HurtadoDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, United States.
Ziyan LinDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, United States.
Christine PampenoDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, United States.
Maria G NovalDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY, United States.
Sara A ThannickalDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY, United States.
Kenneth A StaplefordDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY, United States.
Daniel MerueloDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, United States.
New York University · US

Funding

A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancerR44CA250627 · NCI · CYNVEC, LLC · PI MERUELO, DANIEL, SESSIONS, JENNIFER JUNE · 2020 to 2022
$2.4M
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after ChemotherapyR44CA206606 · NCI · CYNVEC, LLC · PI MERUELO, DANIEL, WINRAM, SCOTT BUDD · 2016 to 2017
$2.0M
NCI NIH HHS R44 CA206606NCI NIH HHS R44 CA250627
6 · The paper itself

Abstract

The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is a major global public threat. Currently, a worldwide effort has been mounted to generate billions of effective SARS-CoV-2 vaccine doses to immunize the world's population at record speeds. However, there is still a demand for alternative effective vaccines that rapidly confer long-term protection and rely upon cost-effective, easily scaled-up manufacturing. Here, we present a Sindbis alphavirus vector (SV), transiently expressing the SARS-CoV-2 spike protein (SV.Spike), combined with the OX40 immunostimulatory antibody (αOX40) as a novel, highly effective vaccine approach. We show that SV.Spike plus αOX40 elicits long-lasting neutralizing antibodies and a vigorous T-cell response in mice. Protein binding, immunohistochemical, and cellular infection assays all show that vaccinated mice sera inhibits spike functions. Immunophenotyping, RNA Seq transcriptome profiles, and metabolic analysis indicate a reprogramming of T cells in vaccinated mice. Activated T cells were found to mobilize to lung tissue. Most importantly, SV.Spike plus αOX40 provided robust immune protection against infection with authentic coronavirus in transgenic mice expressing the human ACE2 receptor (hACE2-Tg). Finally, our immunization strategy induced strong effector memory response, potentiating protective immunity against re-exposure to SARS-CoV-2 spike protein. Our results show the potential of a new Sindbis virus-based vaccine platform to counteract waning immune response, which can be used as a new candidate to combat SARS-CoV-2. Given the T-cell responses elicited, our vaccine is likely to be effective against variants that are proving challenging, as well as serve as a platform to develop a broader spectrum pancoronavirus vaccine. Similarly, the vaccine approach is likely to be applicable to other pathogens.

Indexed as

Angiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntibodies, ViralAntigens, DifferentiationCOVID-19COVID-19 VaccinesCricetinaeFemaleHEK293 CellsHumansMiceMice, Inbred C57BLMice, TransgenicSARS-CoV-2Sindbis VirusACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralAntigens, DifferentiationCOVID-19 VaccinesOX40IgSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2alphavirus vaccineCOVID19SARS-CoV-2 immunitySARS-CoV-2 vaccineSindbis virus vaccinesynergistic combination SARS-CoV-2 vaccine strategyαOX40

Identifiers

PMID34394127
PMCPMC8359677
OpenAlexW3183152223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.